Home | Cardialen

GENTLY RESTORE NORMAL HEART RHYTHM

We understand that an abnormally fast heart rhythm can have a life-altering impact on a patient and family. For those who are living with atrial fibrillation (AF), ventricular tachycardia (VT) or who have had or are at risk of ventricular fibrillation (VF), Cardialen’s MultiPulse™ Therapy (MPT) is an investigational therapy delivering low-energy pulse therapy to potentially restore a normal heart rhythm. Lower energy could minimize painful and potentially damaging side effects associated with current therapies.

DETECT

AND TREAT AF

Learn more >

REDUCE

HIGH-ENERGY SHOCKS

Learn more >

TARGET

MULTIPLE ARRHYTHMIAS USING LOW ENERGY

Learn more >

HOW MULTIPULSE THERAPY WORKS

How MultiPulse Therapy can potentially detect and treat atrial fibrillation (AF), rapid ventricular tachycardia (VT) and ventricular fibrillation (VF).

FIND OUT MORE Explore the latest innovation in tachyarrhythmia technology.

ABOUT US

Advancing cardioversion and defibrillation using low-energy therapy

Cardialen, Inc. is an early-stage medical device company dedicated to advancing implantable cardioversion and defibrillation using low energy for use as a first-line therapy to restore normal heart rhythm and may reduce the potential for high-energy defibrillation shocks.

Our MultiPulse™ Therapy (MPT) is currently being studied in an FDA-approved early feasibility IDE clinical trial exploring how a sequence of low-energy pulses timed to stop abnormal heart rhythms may restore normal heart rhythm using less energy than current high-energy shocks.

CAUTION: Investigational Device. Limited by Federal (United States) law to investigational use only

SENIOR LEADERSHIP

Jeff Peters, President and CEO

Igor Efimov, PhD, Founder

Sumeet Dham, VP Research & Development

Tom Rasmussen, VP Clinical

Michelle Straight, Director of Quality

Kristen Swanson, Director of Regulatory

Jim McCrave, Chief Financial Officer

BOARD OF DIRECTORS

Jeff Peters, President and CEO; Director

Jay Schmelter, RiverVest Venture Partners, LLC; Director